SCHEMBL608410

SCHEMBL608410

CC(=O)CC(=O)N1CCC(=O)c2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.54
RAB9A P51151 3/20 0.52
LMNA P02545 2/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 4/20 0.47
TSHR P16473 3/20 0.47
TP53 P04637 2/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.45
MAPT P10636 4/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HSP90AA1 P07900 1/20 0.41
PAX8 Q06710 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10869086 0.85 LMNA (0.55) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL68594 0.83 NOTUM (0.72) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL23409642 0.80 TSHR (0.71) NOTUMRAB9ALMNAALDH1A1TSHR
SCHEMBL28021992 0.78 LMNA (0.68) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL25937330 0.78 ALDH1A1 (0.51) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL9956661 0.76 LMNA (0.58) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL642025 0.75 NOTUM (0.70) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL25429945 0.75 ALDH1A1 (0.50) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL842907 0.74 HPGD (0.64) NOTUMRAB9ALMNAHTTALDH1A1
SCHEMBL31562020 0.73 LMNA (0.66) NOTUMRAB9ALMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040966-A1 ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZATION AND INTELLECTUAL PROP (US) 2012-02-16 US disclosed
EP-2381944-A1 ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY Southern Research Institute (US) 2011-11-02 EP disclosed
WO-2010078229-A1 ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY SOUTHERN RESEARCH INSTITUTE (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040966-A1 ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY ZC3HAV1, OAT, MAVS NOTUM 1359/4885RAB9A 4055/4885LMNA 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.